MediWound
- Biotech or pharma, therapeutic R&D
MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of innovative biologics that enhance existing standards of care and improve patient experiences while reducing healthcare costs and unnecessary surgeries.
MediWound’s first drug, NexoBrid®, is an FDA- and EMA-approved orphan biologic for debridement of deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for surgical interventions.
Leveraging its proprietary enzymatic technology, MediWound's key pipeline asset is EscharEx®, a promising candidate in Phase III for the debridement of chronic wounds. Phase II clinical trials showed that EscharEx has distinct advantages over the currently available $370+ million drug for wound debridement, presenting a unique opportunity for significant market growth.
www.mediwound.com & LinkedIn.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}